Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2007-05-10
2009-10-20
McGarry, Sean (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023100, C536S024300, C514S04400A
Reexamination Certificate
active
07605251
ABSTRACT:
The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the proprotein convertase subtilisin kexin 9 (PCSK9) gene, comprising an antisense strand having a nucleotide sequence which is less than 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PCSK9 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; and methods for treating diseases caused by PCSK9 gene expression by using the pharmaceutical composition.
REFERENCES:
patent: 6054299 (2000-04-01), Conrad
patent: 6271359 (2001-08-01), Norris et al.
patent: 10100586 (2002-11-01), None
patent: WO 96/40964 (1996-12-01), None
patent: WO 99/32619 (1999-07-01), None
patent: WO 99/53050 (1999-10-01), None
patent: WO 99/61631 (1999-12-01), None
patent: WO 00/22113 (2000-04-01), None
patent: WO 00/22114 (2000-04-01), None
patent: WO 00/44895 (2000-08-01), None
patent: WO 2004/065601 (2004-08-01), None
Gensberg et al., “Subtilin-Related Serine Proteases in the Mammalian Constitutive Secretory Pathway”, Seminars in Cell and Developmental Biology, 1998, vol. 9, pp. 11-17.
Seidah et al., “Proprotein and Prohormone Convertases: A Family of Subtilases Generating Diverse Bioactive Polypeptides”, Brain Research, 1999, pp. 45-62.
Leren, “Mutations in the PCSK9 Gene in Norwegian Subjects with Autosomal Dominant Hypercholesterolemia”, Clinical Genetics, 2004, pp. 419-422.
Shioji et al., “Genetic Variants in PCSK9 Affect the Cholesterol Level in Japanese”, J. Hum Genet, 2004, pp. 109-114.
J.C. Cohen et al., “Molecular Mechanisms of Autosomal Recessive Hypercholesterolemia”, Current Opinion in Lipidology, 2003, 14, pp. 121-127.
Cohen et al, “Low LDL Cholesterol in Individuals of African Descent Resulting from Frequent Mutations in PCSK9”, Nature Genetics, 2005, 37, pp. 161-165.
Yang et al., “Evidence that Processed Small dsRNAs May Mediate Sequence-Specific mRNA Degradation During RNAi in Drosophila Embryos”, Current Biology, 2000, pp. 1191-1200.
Abifadel et al., “Mutations in PCSK9 Cause Autosomal Dominant Hypercholesterolemia”, Nature Genetics, 2003, 34, pp. 154-156.
Li et al., “Folate-Mediated Targeting of Antisense Oligodeoxynucleotides to Ovarian Cancer Cells”, Phar. Research, 1998, 15, pp. 1540-1545.
Templeton et al., “Improved DNA: Liposome Complexes for Increased Systemic Delivery and Gene Expression”, Nature Biotechnology, 1997, 15, pp. 647-652.
Morrissey et al., “Potent and Persistent in Vivo Anti-HBV Activity of Chemically Modified siRNAs”, Nature Biotechnology, 2005, 23, pp. 1002-1007.
Couture et al., “Anti-gene Therapy: The Use of Ribozymes to Inhibit Gene Function”, TIG, 1996, 12, pp. 510-515.
Bergeron et al., “Subtilase-Like Pro-Protein Convertases: from Molecular Specificity to Therapeutic Applications”, Journal of Molecular Endocrinology, 2000, 24, pp. 1-22.
Taylor et al., “Curbing Activation:proprotein Convertases in Homeostasis and Pathology”, FASEB, 17, pp. 1215-1227.
Maxwell et al., “Novel Putative SREBP and LXR Target Genes Identified by Microarray Analysis in Liver of Cholesterol-Fed Mice”, Journal of Lipid Research, 2003, 44, pp. 2109-2119.
Dubuc et al., Arteriosclerosis, Thrombosis, and Vascular Biology, Journal of the American Heart Association, 2004, 24, pp. 1454-1459.
Zhou et al., Proteolytic Processing in the Secretory Pathway, Journal of Biological Chemistry, 1999, 274, pp. 20745-12032.
Timms et al., “A Mutation in PCSK9 Causing Autosomal-Dominant Hypercholesterolemia in a Utah Pedigree”, Humm Genet, 2004, 114, pp. 349-353.
Maxwell et al., “Adenoviral-Mediated Expression of Pcsk9 in Mice Results in a Low-Density LipoProtein Receptor Knockout Phenotype”, Proc. Acad. Sci. USA, 2004, 101, 7100-7105.
Rader et al., “Monogenic Hypercholesterolemia: New Insights in Pathogenesis and Treatment”, Journal of Clinical Investigation, 2003, 111, pp. 1795-1803.
Benjannet et al., “NARC-1/PCSK9 and it's Natural Mutants”, Journal of Biological Chemistry, 2004, 279, pp. 48865-48875.
Park et al., “Post-Transcriptional Regulation of Low Density Lipoprotein Receptor Protein by Proprotein Convertase Subtilisin/Kexin Type 9a in Mouse Liver”, Journal of Biological Chemistry, 2004, 279, pp. 50630-50638.
Rashis et al., “Decreased Plasma Cholesterol and Hypersensitivity to Statins in Mice Lacking Pcsk9”, PNAS, 2005, 102, pp. 5374-5379.
Cohen et al., “Sequence Variations in PCSK9, Low LDL, and Protection Against Coronary Heart Disease”, New England Journal of Medicine, 2006, 354, pp. 1264-1272.
Gassman et al., “Maintenance of an Extrachromosomal Plasmid Vector in Mouse Embryonic Stem Cells”, Proc. Natl. Acad, Sci., 1995, 92, pp. 1292-1296.
Elbashir et al., “Functional Anatomy of siRNAs for Mediating Efficient RNAi inDrosophila melanogasterEmbryo Lysate”, 2001, 20, pp. 6877-6888.
Manoharan, “Oligonucleotide Conjugates as Potential Antisense Drugs with Improved Uptake, Biodistribution, Targeted Delivery, and Mechanism of Action”, Antisense & Nucleic Acid Drug Development, 2002, 12 pgs. 103-128.
NM 174936, NCBI, 2006, pp. 1-5.
NM 153565, NCBI, 2006, pp. 1-4.
NM 199253, NCBI, 2006, pp. 1-4.
Basek, “Inhibitors of Proprotein Convertases”. Journal of Molecular Medicine, 2002, 83, pp. 844-855.
Graham et al., “Antisense Inhibition of Proprotein Convertase Subtilism/Kexin Type 9 Reduces Serum LDL in Hyperlipidemix Mice”, Journal of Lipid Research, 2007, 48, pp, 767-769.
Lu et al., “Delivering siRNA in Vivo for Functional Genomics and Novel Therapeutics in RNA Interference Technology”, Cambridge, Appasani, 2005, pp. 303-317.
Downward, “Science, Medicine, and the Future RNA Interference”, BMJ, 328, pp. 1245-1248.
Samarsky et al., “RNAi in Drug development: Practical Considerations in RNA Interference Technology”, Cambridge, Appasani, 2005, pp. 384-395.
Graham et al., “Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice,” Journal of Lipid Research, 48: 763-767 (2007).
Genbank Accession No. NM—174936.Homo sapiensproprotein convertase subtilisin/kexin type 9 (PCSK9), mRNA. Sep. 30, 2007, p. 1-5.
International Search Report and the Written Opinion for PCT/US07/68655 dated Oct. 29, 2007.
Akinc Akin
Bramlage Birgit
Fitzgerald Kevin
Frank-Kamenetsky Maria
Kotelianski Victor E.
Alnylam Pharmaceuticals, Inc.
Fenwick & West LLP
Gibbs Terra Cotta
McGarry Sean
LandOfFree
Compositions and methods for inhibiting expression of the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for inhibiting expression of the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for inhibiting expression of the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4141830